Core Insights - Autolus Therapeutics presented preliminary data from the CATULUS Phase 1 trial of obe-cel for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) at the ASH Annual Meeting, highlighting high remission rates and a favorable safety profile [1][2][3] Group 1: Pediatric Trial Insights - The CATULUS trial showed an overall response rate (ORR) of 95.5% in pediatric patients, with 90.9% achieving complete response (CR) [3] - The safety profile of obe-cel in pediatric patients was consistent with adult data, showing low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), both at 8.7% [3][4] - Twenty patients remained in ongoing remission at the data cut-off with a median follow-up of 8.8 months, supporting further exploration of obe-cel in this population [3] Group 2: Adult Trial Insights - Insights from the FELIX pivotal trial indicated that the detection of obe-cel in the blood three months post-treatment may predict long-term outcomes in adult patients with r/r B-ALL [2][4] - The analysis of the FELIX study revealed that a higher percentage of central memory cells in the drug product was an independent predictor of positive clinical outcomes, including overall survival [7] Group 3: Real-World Data - Real-world data from the ROCCA consortium corroborated the safety profile of obe-cel, showing low rates of high-grade CRS and ICANS, consistent with clinical trial results [2][4] Group 4: Product Characteristics - The unique features of the CAR T product, including the CAT19 binder, were highlighted as important for tracking CAR T expansion and persistence, which are critical for predicting treatment outcomes [6][7] - The study emphasized the need for further investigations to understand the impact of tumor characteristics and product features on clinical outcomes [7]

Core Viewpoint - Aura Minerals Inc. has announced the results of the Feasibility Study for the Era Dorada Project, indicating a robust economic outlook with significant gold production potential and favorable financial metrics [1][3]. Project Overview - The Era Dorada Project is located in Jutiapa, Guatemala, approximately 160 km from Guatemala City and near the El Salvador border [4]. - The project is an underground gold mine with an expected production of 111,000 gold equivalent ounces (GEO) annually for the first four years, totaling approximately 1.75 million GEO over a life of mine (LOM) of 16.8 years [3][5]. Financial Metrics - The Feasibility Study indicates an after-tax Net Present Value (NPV) of US$2.17 billion at spot prices of US$4,200 per ounce of gold, with an after-tax Internal Rate of Return (IRR) of 68% [3]. - The project has a competitive All-In Sustaining Cost (AISC) of US$1,178 per ounce during the LOM, with an initial capital expenditure (Capex) of US$382 million and a payback period of approximately 2.82 years [3][5]. Production and Cost Estimates - Average production is projected at 111,000 GEO for the first four years, with a total payable gold of 4,852,000 ounces over the LOM [8]. - The average cash cost is estimated at US$993 per ounce, with an AISC of US$1,178 per ounce [8][9]. Mineral Resource and Reserve Estimates - The project has Proven and Probable Mineral Reserves of 1.75 million GEO, with an average grade of 6.23 grams per tonne [5][30]. - Exclusive Indicated Mineral Resources are estimated at 523,000 GEO, assuming 2.46 million tonnes at 6.61 grams per tonne [5][27]. Mining and Processing Plan - The mining method will primarily utilize sublevel long hole stoping, contributing approximately 98.5% of total metal production [33]. - The processing plant is designed to treat 1,600 tons per day, employing conventional methods including gravity concentration and cyanide leaching [39][40]. Environmental and Social Considerations - The company is working closely with local authorities to ensure compliance with environmental and social standards, aligning with its Aura 360 culture [3].

Dispensary Opening Brings Expanded Access to Premium Products, Introduces New Brands and Delivers an Elevated Patient ExperienceNEW YORK and TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates and partners with regulated cannabis operations across the United States, has announced its expansion into St. Petersburg with the opening of its 25th GrowHealthy dispensary in Florida. The new St. Petersburg location ope ...

Actelis technology selected to support a major carrier’s multi-state customer base to modernize legacy T1 and TDM networks in the United States Recent U.S. government FCC proposal to accelerate copper-network retirements may create further demand for modernization solutions such as Actelis’ technology SUNNYVALE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and bro ...

FUKUOKA, Japan, Dec. 08, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company"), a Japanese labor consulting and health services company, announced that its health services subsidiary, Sakai Seikotsuin Nishi Co., Ltd. (“Sakai Seikotsuin”), was selected by the 2025 Taipei Wake Open as an official provider of trainer and on-site medical support services. The Taipei Wake Open, now in its 10th year, is recognized as one of Asia’s largest watersports competitions, drawing top wa ...

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The C ...

Core Insights - Orion Energy Systems, Inc. will participate in Singular Research's 19th Annual Best of the Uncovereds Conference on December 11, 2025, highlighting its focus on energy-efficient solutions [1] - CEO Sally Washlow will present virtually and engage in one-on-one investor meetings during the event, indicating the company's commitment to investor relations [2] Company Overview - Orion specializes in energy efficiency and clean tech solutions, including LED lighting, EV charging solutions, and maintenance services, aiming to help customers achieve business and environmental goals [3] - The company offers turnkey design-through-installation solutions for large national customers and collaborates with ESCO and distribution partners [3] - Orion is dedicated to sustainability and responsible operations across its organization, with a focus on reducing carbon footprints and enhancing business performance [4]

WAYNE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that it will host a virtual fireside chat on Tuesday, December 16, 2025, at 11:00 a.m. ET. Charles Allen, CEO of BTCS, will provide an update on the Company’s recent progress following the release of its Q3 2025 earnings. Mr. Allen plans to highlight BTCS’s Ethereum-first growth strategy, including the ...

SCOTTSDALE, Ariz., Dec. 08, 2025 (GLOBE NEWSWIRE) -- SolarWindow Technologies, Inc. (Symbol: WNDW), developer of transparent electricity-generating coatings for glass and plastics, today released the following year-end shareholder letter from President & CEO Amit Singh. Dear Shareholders, As 2025 draws to a close, I want to share a brief reflection on the progress we’ve made and how we are positioning SolarWindow for the opportunities ahead in 2026. Since being appointed President & CEO last year, my team ...

TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that its peer-reviewed paper, “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” has been accepted for publication in np ...